AstraZeneca PLC (Mexico) Insiders

AZNN Stock  MXN 1,384  6.50  0.47%   
AstraZeneca PLC employs about 48 people. The company is managed by 30 executives with a total tenure of roughly 224 years, averaging almost 7.0 years of service per executive, having 1.6 employees per reported executive. Break down of AstraZeneca PLC's management performance can provide insight into the company performance.
Pascal Soriot  CEO
CEO, Executive Director and Member of Disclosure Committee
Leif Johansson  Chairman
Non-Executive Independent Chairman of the Board
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

AstraZeneca PLC Management Team Effectiveness

The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.

AstraZeneca PLC Workforce Comparison

AstraZeneca PLC is rated second in number of employees category among its peers. The total workforce of Drug Manufacturers—General industry is presently estimated at about 219. AstraZeneca PLC totals roughly 48.0 in number of employees claiming about 22% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of 0.07 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.19 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.19.

AstraZeneca PLC Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. AstraZeneca PLC Price Series Summation is a cross summation of AstraZeneca PLC price series and its benchmark/peer.

AstraZeneca PLC Notable Stakeholders

An AstraZeneca PLC stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AstraZeneca PLC often face trade-offs trying to please all of them. AstraZeneca PLC's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AstraZeneca PLC's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Pascal SoriotCEO, Executive Director and Member of Disclosure CommitteeProfile
Leif JohanssonNon-Executive Independent Chairman of the BoardProfile
Jose BaselgaExecutive Vice President - Research & Development OncologyProfile
Katarina AgeborgExecutive Vice President - Sustainability, Chief Compliance OfficerProfile
Fiona CicconiExecutive Vice President - Human ResourcesProfile
Leon WangExecutive Vice President - International and China PresidentProfile
Pam ChengExecutive Vice-President of Operations and Information TechnologyProfile
Ruud DobberExecutive Vice President, BioPharmaceuticals BusinessProfile
David FredricksonExecutive Vice-President Global Head Oncology Business UnitProfile
Menelas PangalosExecutive Vice President - Research & Development BioPharmaceuticalsProfile
Iskra ReicExecutive Vice President - Europe and CanadaProfile
Marc DunoyerChief Financial Officer, Executive DirectorProfile
Sherilyn McCoyNon-Executive Independent DirectorProfile
Genevieve BergerNon-Executive Independent DirectorProfile
Nazneen RahmanNon-Executive Independent DirectorProfile
Tony MokNon-Executive Independent DirectorProfile
Deborah DiSanzoNon-Executive Independent DirectorProfile
Michel DemareNon-Executive Independent DirectorProfile
Graham ChipchaseSenior Non-Executive Independent DirectorProfile
Philip BroadleyNon-Executive Independent DirectorProfile
Marcus WallenbergNon-Executive DirectorProfile
Deborah EldracherNon-Executive Independent DirectorProfile
Euan AshleyNon-Executive DirectorProfile
Chris SheldonHead RelationsProfile
Adrian KempCompany SecretaryProfile
Diana LayfieldNon-Executive DirectorProfile
MBA DVMCEO DirectorProfile
Aradhana MDCFO DirectorProfile
Jeffrey PottGeneral CounselProfile
Gonzalo VinaHead RelationsProfile

About AstraZeneca PLC Management Performance

The success or failure of an entity such as AstraZeneca PLC often depends on how effective the management is. AstraZeneca PLC management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AstraZeneca management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AstraZeneca management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. ASTRAZENECA operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 76100 people.
Please note, the imprecision that can be found in AstraZeneca PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AstraZeneca PLC. Check AstraZeneca PLC's Beneish M Score to see the likelihood of AstraZeneca PLC's management manipulating its earnings.

AstraZeneca PLC Workforce Analysis

Traditionally, organizations such as AstraZeneca PLC use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AstraZeneca PLC within its industry.

AstraZeneca PLC Manpower Efficiency

Return on AstraZeneca PLC Manpower

Revenue Per Employee924M
Revenue Per Executive1.5B
Net Income Per Employee68.5M
Net Income Per Executive109.6M

Additional Tools for AstraZeneca Stock Analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.